Physician profile
Stephanie Ward
NPI 1639313521
$1,731.09
in general payments reported to CMS, 2019-2025
12 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2021: $167 · 2022: $311 · 2023: $442 · 2024: $428 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $230.05 | 2022-2023 | |
| Genentech USA, INC. | $227.97 | 2021-2024 | Xolair |
| Genzyme Corporation | $222.14 | 2023-2025 | |
| Glaxosmithkline, LLC. | $205.35 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.97 | 2024-2025 | Takhzyro |
| Grifols USA, LLC | $124.99 | 2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $121.87 | 2019 | |
| Abbvie INC. | $107.79 | 2023 | |
| Aimmune Therapeutics, INC. | $105.07 | 2022 | |
| Biocryst US Sales Co., LLC | $89.86 | 2023 | Orladeyo |
| Pfizer INC. | $64.53 | 2019 | |
| Alk-Abello, INC | $61.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.